Micro Medical Solutions (MMS), an innovative medical device company focused on improving outcomes for patients suffering fromCritical Limb Threatening Ischemia (CLTI), today announced the appointment ofVince BurgessandJohn Dahldorfto itsBoard of Directors. They joinGeorge Quinoy, Chairman of the Board and President & Chief Executive Officer, andDr. Ron Solar, Board Member, as MMS strengthens its leadership team in preparation for commercialization of itsMicroStent™technology.
https://mma.prnewswire.com/media/2293608/micromedical_solutions_Logo.jpg
“We are pleased to welcome Vince and John to the MMS Board,”saidGeorge Quinoy, Chairman, President & CEO of Micro Medical Solutions.”Their combined expertise in scaling medical device companies, managing public-company operations, and guiding financial and commercial execution will be invaluable as we advance through FDA review and prepare for market launch.”
Joining the MMS Board in November 2025, Vince Burgess most recently served as President, CEO, and Director of Acutus Medical, Inc.from 2017-2022. He previously was aVenture Partner with OrbiMed Advisors, a global healthcare investment firm, and a founding executive atVolcano Corporation, where he served asPresident of Advanced Imaging Systemsand led marketing and business development from 2002 to 2010. Mr. Burgess currently serves on theBoard of Directors of Tela Bio, Inc.and has held prior board roles with Bolt Medical, NeuroPace, Sonendo, Keystone Heart, Vessix Vascular, Cryterion Medical, and CardiAQ. He earned aB.S. in Business Administrationfrom theUniversity of Southern Californiaand anM.B.A.from theUniversity of California, Los Angeles.
John Dahldorfbrings more than 25 years of experience leading finance and accounting functions for both public and private healthcare companies. He currently serves asChief Financial Officer of Q'Apel Medical, Inc., a neurovascular device company, and as aBoard Member of Hyperfine, Inc. Mr. Dahldorf previously served as Chief Financial Officer for Volcano Corporation where he was instrumental in the acquisition by Royal Philips. He also served as CFO at Digirad Corporation, Acutus Medical, SCN Bestco, andAdagio Medical Holdings. He holds aB.S. in Financeand anM.B.A.fromWestern Illinois University.
“Vince and John each bring proven leadership in innovation, commercialization, and financial strategy,”saidDr. Ron Solar, Board Member.”Their experience will strengthen MMS's ability to execute effectively as we move toward approval and market readiness.”
TheMicroStent™, which has receivedFDA Breakthrough Device Designation, is designed to improve blood flow, promote wound healing, and reduce amputations in patients with CLTI. The device is currently underPremarket Approval (PMA) review.
AboutMMS
Micro Medical Solutions (MMS) is an innovative medical device company addressing the critical unmet need in BTK arterial disease. Our technology is designed to treat patients at high risk of amputation-driven by global health trends including diabetes, hypertension, and aging populations. We are positioned at the intersection of significant clinical demand, regulatory momentum, and market opportunity.
For more information: www.micromedicalsolutions.net.
https://edge.prnewswire.com/c/img/favicon.png?sn=NE25366&sd=2025-11-14
View original content to download multimedia:https://www.prnewswire.com/news-releases/micro-medical-solutions-expands-board-of-directors-with-appointment-of-vince-burgess-and-john-dahldorf-302616089.html
SOURCE Micro Medical Solutions
https://rt.newswire.ca/rt.gif?NewsItemId=NE25366&Transmission_Id=202511141703PR_NEWS_USPR_____NE25366&DateId=20251114